Non‐invasive assessment of liver fibrosis in chronic viral hepatitis

Orășan, Olga Hilda; Iancu, Mihaela Adela; Sava, Madalina; Saplontai-Pop, Aniela; Cozma, Angela; Sarlea, Simina Tarmure; Lungoci, Corneliu; Ungureanu, Marius; Negrean, Vasile; Sampelean, Dorel; Dumitraşcu, Dan L.

doi:10.1111/eci.12543

Cited by 16 publications

(16 citation statements)

References 49 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FibroScan, ASAT-to-platelet ratio index (APRI) and fibrosis 4 score (FIB4) are useful noninvasive tests for the evaluation of liver fibrosis (F) stage 4 in patients with chronic viral hepatitis B or C was the main conclusion of our study published in 2015 [54]. We have new data, which reinforces this statement for haemodialysis patients with chronic viral hepatitis.…”

Section: Detection Of Central Venous Catheter-related Bloodstream Infsupporting

confidence: 71%

“…Noninvasive assessment of liver fibrosis in chronic viral hepatitis [54] (Olga Hilda Orasan and Dan Lucian Dumitrascu)…”

Section: Detection Of Central Venous Catheter-related Bloodstream Infmentioning

confidence: 99%

“…X [54] FibroScan, ASAT to platelet ratio index (APRI) and fibrosis 4 score (FIB4) are useful non-invasive tests for the evaluation of fibrosis stage 4 in patients with chronic hepatitis B and chronic hepatitis C.…”

Section: [50]mentioning

confidence: 99%

See 2 more Smart Citations

Research update for articles published in EJCI in 2015

et al. 2017

Self Cite

View full text Add to dashboard Cite

Section: Detection Of Central Venous Catheter-related Bloodstream Infsupporting

confidence: 71%

“…Noninvasive assessment of liver fibrosis in chronic viral hepatitis [54] (Olga Hilda Orasan and Dan Lucian Dumitrascu)…”

Section: Detection Of Central Venous Catheter-related Bloodstream Infmentioning

confidence: 99%

See 1 more Smart Citation

Research update for articles published in EJCI in 2015

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…And this technique has recently been challenged by the development of several novel noninvasive tests, relying on quantification of serum markers of liver fibrosis, measurement of liver stiffness by imaging techniques, or the combination of these two approaches. The last decade has witnessed the rapid progress in developing serum markers for the prediction and diagnosis of hepatic fibrosis, such as APRI Score, Fibro Test, FIB-4 index, Hui Score, Zeng Score, etc 56…”

mentioning

confidence: 99%

Predictive Value of Serum IFN-γ inducible Protein-10 and IFN-γ/IL-4 Ratio for Liver Fibrosis Progression in CHB Patients

Wang

Shen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Noninvasive serum markers for assessment of liver fibrosis in chronic hepatitis B (CHB) patients have not been well-studied. The present study was to evaluate the predictive value of serum interferon gamma-inducible protein-10 (IP-10/CXCL10) and the interferon (IFN)-γ/interleukin (IL)-4 ratio for liver fibrosis progression in CHB patients. A total of 180 CHB patients were categorized into four groups: no fibrosis, mild fibrosis, moderate fibrosis, and severe fibrosis. Serum and intrahepatic levels of IP-10, IFN-γ, and IL-4 were examined, from which the IFN-γ/IL-4 ratio was calculated. We found that the serum IP-10 levels were positively correlated with the severity of liver fibrosis, whereas the IFN-γ/IL-4 ratio was negatively associated with the progression of hepatic fibrosis. Multivariate logistic regression analysis revealed that the serum IP-10 was an independent predictor for significant fibrosis. For predicting significant fibrosis, the IP-10 cut-off value of 300 ng/mL had a sensitivity of 92.7% and a specificity of 68.6%. When the IP-10 level was combined with the IFN-γ/IL-4 ratio, the specificity and positive predictive value were 93.8% and 94.6%, respectively; thus, the discriminatory ability was much improved. In conclusion, the serum IP-10 level and the IFN-γ/IL-4 ratio have great potential to predict significant fibrosis among CHB patients.

show abstract

“…A recent study detected the F4 cut-off value for APRI to be 0.7[20]. This cut-off would have missed 2/6 (33.3%) F4 patients in our study.…”

Section: Discussionmentioning

confidence: 75%

Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis

Wong

Huynh

Zhang

2017

WJH

View full text Add to dashboard Cite

AIMTo evaluate the performance of aspartate aminotransferase to platelet ratio (APRI) score against FibroScan in predicting the presence of fibrosis.METHODSData of patients who concurrently had APRI score, FibroScan and liver biopsy to assess their hepatitis C virus (HCV) and hepatitis B virus (HBV) over 6 years were retrospectively reviewed and details of their disease characteristics and demographics were recorded. Advanced fibrosis was defined as ≥ F3.RESULTSOf the 3619 patients (47.5 ± 11.3 years, 97M:36F) who had FibroScans and APRI for HCV and HBV, 133 had concurrent liver biopsy. Advanced liver fibrosis was found in 27/133 (20%, F3 = 21 and F4 = 6) patients. Although APRI score (P < 0.001, AUC = 0.83) and FibroScan (P < 0.001, AUC = 0.84) predicted the presence of advanced fibrosis, the sensitivities and specificities were only modest (APRI score: 51.9% sensitivity, 84.9% specificity; FibroScan: 63% sensitivity, 84% specificity). Whilst 13/27 (48%) patients with advanced fibrosis had APRI ≤ 1.0, no patients with APRI ≤ 0.5 had advanced fibrosis, with 100% sensitivity. The use of APRI ≤ 0.5 would avoid the need for FibroScan in 43% of patients.CONCLUSIONAPRI score and FibroScan performed equally well in predicting advanced fibrosis. A proposed APRI cut-off score of 0.5 could be used as a screening tool for FibroScan, as cut-off score of 1.0 will miss up to 48% of patients with advanced fibrosis. Further prospective validation studies are required to confirm this finding.

show abstract

Non‐invasive assessment of liver fibrosis in chronic viral hepatitis

Abstract: FibroScan, APRI and FIB4 are useful non-invasive tests for the evaluation of F4 in patients with CHB and CHC.

Cited by 16 publications

References 49 publications

Research update for articles published in EJCI in 2015

Research update for articles published in EJCI in 2015

Predictive Value of Serum IFN-γ inducible Protein-10 and IFN-γ/IL-4 Ratio for Liver Fibrosis Progression in CHB Patients

Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis

Contact Info

Product

Resources

About